ArticleScientific reports2026
Mucosal DNA methylation reveals immune-related methylation profile and correlates with crohn's disease status.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanisms and therapeutic prospects of DNA methylation-mucosal innate immunity crosstalk in inflammatory bowel disease.Frontiers in immunology · 2026Review
- The role of calcium homeostasis dysregulation in allergic rhinitis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Altered DNA methylation (DNAm) patterns have been proven to play a key role in Crohn's disease (CD) pathogenesis. However, DNAm and its association with disease status in Chinese CD remain unclear. This study systematically examines DNAm patterns in Chinese patients with CD and their association with disease status. By elucidating specific DNAm alterations involved in CD pathogenesis, it aims to provide a molecular foundation for early diagnosis, prognosis assessment, and personalized treatment strategies. In this study, 24 adult treatment-naïve patients with CD were enrolled between January 2022 and May 2023. We performed reduced representation bisulfite sequencing (RRBS) on paired inflamed and non-inflamed intestinal mucosa samples from these patients, and inflammation-specific and disease severity-specific differential methylation signatures were identified. A total of 17,097 differentially methylated sites (DMCs) and 2,687 differentially methylated regions (DMRs) were identified in inflamed mucosa. Biological association analysis revealed that inflammation-associated DMRs were enriched in immune function, with 123 DMRs annotating 89 genes involved in immune cell function while 173 DMRs annotating 117 genes participated in cell adhesion function. Analysis of DNAm profiles of inflamed mucosal samples by disease severity revealed that 389 DMRs were associated with the Simple Endoscopic Score for Crohn's Disease (SES-CD) and 327 DMRs with the Crohn Disease Activity Index (CDAI). Of these, six genes, KDM4B, CLDN15, PGGHG, SLC25A10, KIAA2013, and N4BP1, were significantly associated with inflammation, SES-CD and CDAI. Hence, DNAm reflects immunological changes in the gut of CD patients and discriminates patients based on disease severity, highlighting its potential as a predictive marker for disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.